Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Children With Active Oral Ulcers Associated With Behçet's Disease
NCT04528082Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Sep 2021
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of apremilast in Behçet's disease (BD), sponsored by Amgen. Started Sep 2021; status: recruiting.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT04528082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528082.